What are the recommended pediatric and adult doses of polyethylene glycol (PEG 3350) for treating constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Polyethylene Glycol Dosing

For adults with chronic constipation, use polyethylene glycol 3350 at 17 g once daily, and for children, start with 0.4 g/kg/day (approximately 0.8 g/kg/day for maintenance therapy). 1

Adult Dosing

The FDA-approved and guideline-recommended dose for adults is 17 g once daily, mixed in 4-8 ounces of any beverage 1, 2. This dose:

  • Is approved for occasional constipation but has demonstrated efficacy for chronic idiopathic constipation for up to 6 months 1
  • Can be titrated based on symptom response and side effects with no clear maximum dose 1
  • Should be fully dissolved before drinking; do not use if clumps remain 2

Key adult considerations:

  • The 17 g daily dose significantly increases complete spontaneous bowel movements (mean difference 2.90 per week) and overall bowel movement frequency (mean difference 2.30 per week) compared to placebo 1
  • Response is durable over 6 months of continuous use 1
  • For acute relief within 24 hours, higher doses (68 g as a single dose) have been studied but are not standard practice 3

Pediatric Dosing

For Functional Constipation (Maintenance):

Start with 0.4 g/kg/day for children aged 2 years and older 4. This dose can be adjusted every 3 days to achieve 2 soft stools per day, with an effective range of 0.27-1.42 g/kg/day (mean effective dose 0.8 g/kg/day) 5.

Specific pediatric evidence:

  • The 0.4 g/kg/day dose significantly improved bowel movement frequency and stool consistency with fewer side effects than higher doses 4
  • The 0.8 g/kg/day dose, while effective, caused more abdominal pain and fecal incontinence 4
  • Mean effective maintenance dose across studies is approximately 0.74-0.84 g/kg/day 5

For Children Under 2 Years:

Consult a physician - FDA labeling recommends asking a doctor for children 16 years and under, though real-world data shows usage in children under 2 years with a median dose of one sachet (6.9 g) daily 2, 6. Safety data in this age group shows no concerning signals, but electrolyte monitoring may be prudent 6.

For Home Cleanouts (Disimpaction):

Pediatric gastroenterology practices use significantly higher doses:

  • 1-day cleanout: median 5.3 g/kg/day 7
  • 2-day cleanout: median 4.6 g/kg/day 7

These doses are substantially higher than standard maintenance dosing and should be used under specialist guidance.

Practical Administration

Mixing instructions:

  • Dissolve powder completely in 4-8 ounces of any temperature beverage (cold, hot, or room temperature) 2
  • Do not combine with starch-based thickeners used for dysphagia 2
  • Ensure adequate hydration throughout treatment 1

Duration:

  • FDA labeling states "do not use more than 7 days" for over-the-counter use 2
  • However, clinical evidence supports safe use for up to 6 months for chronic constipation 1

Common Pitfalls to Avoid

  1. Underdosing in children: The 0.2 g/kg/day dose, while effective, is less optimal than 0.4 g/kg/day for symptom control 4

  2. Inadequate dissolution: Drinking incompletely dissolved powder reduces efficacy and palatability 2

  3. Premature discontinuation: Most gastrointestinal side effects (bloating, cramping) occur in the first week and decrease markedly thereafter 8

  4. Ignoring dose titration: The dose should be adjusted based on stool frequency and consistency, not arbitrarily maintained 1

Expected Side Effects

Common and generally mild side effects include 1:

  • Bloating and abdominal discomfort
  • Flatulence
  • Diarrhea (158 more per 1,000 treated patients)
  • Cramping

These effects are consistent with osmotic laxative therapy and most are mild to moderate in severity. Serious adverse events are rare with no significant difference from placebo 1.

Related Questions

What is the appropriate dose of MiraLAX (polyethylene glycol 3350) for a 2‑year‑old child weighing approximately 12–14 kg?
What is the typical acute dose of macrogol (polyethylene glycol 3350) for children with mild encopresis or constipation?
What is the appropriate dosage of polyethylene glycol 3350 (MiraLAX) for a 2.5-year-old child weighing 14 kg with constipation?
What is the appropriate dose of polyethylene glycol 3350 (Miralax) for a 3‑year‑old child weighing 32 lb (≈14.5 kg) with constipation?
What is the recommended dose of Movicol (polyethylene glycol 3350 + electrolytes) for children?
A patient with pneumonia received cefuroxime 750 mg three times daily instead of the recommended 1500 mg three times daily for five days, then stopped and subsequently deteriorated; should the antibiotic be restarted at the correct dose, is cefuroxime ineffective or sub‑therapeutic, or should the regimen be switched to a different antibiotic?
What is the appropriate pediatric dosing regimen for lactulose?
Do patients with a reduced left ventricular ejection fraction have an increased risk of acute pulmonary edema?
What is the appropriate treatment for a patient with migraine accompanied by psychotic symptoms?
In a patient with pneumonia who was given cefuroxime 750 mg intravenously three times daily (instead of the recommended 1500 mg three times daily) for five days, then stopped therapy and subsequently deteriorated, should cefuroxime be restarted at the correct dose, is the prior regimen considered sub‑therapeutic/ineffective, or should the antibiotic regimen be switched to a broader‑spectrum agent?
Based on a CBC showing mild normocytic anemia (hemoglobin 11.5 g/dL, hematocrit 37.1 %, MCV 86.3 fL) with elevated RDW, low‑normal white blood cell count (4.0 K/µL) and absolute neutrophil count 1.2 K/µL (neutropenia) and increased monocyte count 0.7 K/µL, what is the likely interpretation and recommended management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.